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Insulin resistance (IR) and impaired glucose tolerance (IGT) are the first manifestations 37 
of diet-induced metabolic alterations leading to type-2 diabetes, while hypertension is 38 
the deadliest risk factor of cardiovascular disease. The roles of dietary fat and fructose 39 
in the development of IR, IGT and hypertension are controversial.  40 
We tested the long-term effects of an excess of fat or sucrose (fructose/glucose) on 41 
healthy male Wistar Kyoto (WKY) rats. Fat affects IR and IGT earlier than fructose 42 
through low-grade systemic inflammation evidenced by liver inflammatory infiltration, 43 
increased levels of plasma interleukin-6, prostaglandin E2 and reduced levels of 44 
protective short-chain fatty acids without triggering hypertension. Increased populations 45 
of gut Enterobacteriales and Escherichia coli may contribute to systemic inflammation 46 
through the generation of lipopolysaccharides. Unlike fat, fructose induces increased 47 
levels of diacylglycerols (lipid mediators of IR) in the liver, urine F2-isoprostanes 48 
(markers of systemic oxidative stress) and uric acid, and triggers hypertension. Elevated 49 
populations of Enterobacteriales and E. coli were only detected in rats given an excess 50 
of fructose at the end of the study. 51 
Dietary fat and fructose trigger IR and IGT in clearly differentiated ways in WKY rats: 52 
early low-grade inflammation and late direct lipid toxicity, respectively; gut microbiota 53 
plays a role mainly in fat-induced IR; and hypertension is independent of inflammation-54 
mediated IR. The results provide evidence which suggests that the combination of fat 55 
and sugar is potentially more harmful than fat or sugar alone when taken in excess. 56 
57 
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3INTRODUCTION 59 
Obesity and type 2 diabetes (T2D) together with hypertension and 60 
hypercholesterolemia are the main risk factors of cardiovascular disease (CVD), the 61 
leading cause of death worldwide. An unhealthy lifestyle, the combination of a poor diet 62 
with physical inactivity, is the single greatest contributor to the appearance of all these 63 
warning signs (36). Obesity, insulin resistance (IR, first revealed by high fasting 64 
insulinemia) and impaired glucose tolerance (IGT) appear to be the first manifestations 65 
of the so-called metabolic syndrome (12), and hypertension is probably the deadliest 66 
CVD triggering factor (16).  67 
The relationships between fat accumulation, IR and hypertension are still unclear in 68 
both humans and animal models. Whereas most diet-induced rodent models of obesity 69 
and/or hypertension are insulin resistant, they show significant differences. Rats fed a 70 
high-fat diet become overweight but rarely develop hypertension unless their diet is 71 
supplemented with salt (1, 39); while those fed a high-fructose or high-sucrose (50% 72 
fructose) diet may become hypertensive while remaining normoweight (10, 40, 49). 73 
There is wide consensus that ectopic lipid accumulation in key organs such as liver and 74 
muscle originates IR, but how particular lipids contribute to systemic IR and the 75 
relevance of their location is an active area of research (44). Visceral adipose tissue (AT) 76 
has been associated with low-grade inflammation and the metabolic complications of 77 
obesity, mainly because it releases free fatty acids and pro-inflammatory adipokines into 78 
the portal vein for direct transport to the liver (9, 14). Meanwhile, particular lipids such 79 
as diacylglycerols (DAGs) and ceramides may impair insulin signaling in liver and 80 
muscle independently of inflammation by altering the phosphorylation pattern of the 81 
insulin receptor substrate (IRS): a key protein in the intracellular insulin signaling 82 
pathway (13, 44). DAGs may be formed from triacylglycerides (TAGs) by lipolysis or 83 
4via de novo synthesis of TAGs from free fatty acids (13).  84 
The relationship between IR and hypertension is also a controversial issue. Whereas 85 
it has been proposed that IR is the main upstream event leading to hypertension (49), 86 
other evidence suggests that different factors may increase blood pressure more 87 
decisively than IR (27).  88 
As it is becoming evident that diet-induced changes in populations of gut 89 
microbiota play a role in the development of obesity and related disorders (42), the 90 
study of the crosstalk between the host organism and its associated microbiota is 91 
emerging as an active area of research. Specifically, gut microbiota has been shown to 92 
trigger IR through the action of pro-inflammatory products of bacterial metabolism (3).  93 
To substantiate preventive dietary strategies against metabolic alterations, it is 94 
important to characterize early pre-disease events and to define molecular and 95 
physiological markers that are suitable for evaluating nutritional or behavioral 96 
interventions. As the molecular mechanisms linking lipid accumulation, IR and 97 
hypertension are still largely unknown, we compared two animal models of diet-induced 98 
metabolic changes: Wistar Kyoto (WKY) rats fed a high-fat (HF) or high-sucrose (HS) 99 
diet. Both models develop incipient IR and/or IGT, while only the HS-fed rats become 100 
hypertensive. This paper focuses on the differential mechanisms associated with dietary 101 
fat and sugar (fructose) as triggering factors of IR, IGT and hypertension, and it 102 
examines the possible role played by gut microbiota in these effects.  103 
104 
5MATERIALS AND METHODS 105 
106 
Animals. A total of twenty-seven male WKY rats (Envigo, Indianapolis, IN, USA), 107 
aged 8-9 weeks were used. All animal manipulation was carried out in the morning to 108 
minimize the effects of circadian rhythms. All the procedures strictly adhered to the 109 
European Union guidelines for the care and management of laboratory animals 110 
(directive 2010/63/UE) under license from the regional Catalan authorities (reference 111 
no. DAAM7921), and approved by the Spanish CSIC Subcommittee of Bioethical 112 
Issues.113 
Experimental design and sample collection. The rats were housed (n = 3 per cage) 114 
under controlled conditions of humidity (60%), and temperature (22 ± 2 ºC) with a 12 h 115 
light-12 h dark cycle. They were randomly divided into 3 dietary groups (n = 9 per 116 
group): the standard (STD) group, fed a standard diet (2014 Teklad Global 14% Protein 117 
Diet from Envigo) and mineral water (Ribes, Girona, Spain); the high-fat (HF) group, 118 
fed an HF diet (TD 08811 45% kcal Fat Diet, from Envigo) and mineral water; and the 119 
high-sucrose (HS) group, fed the standard diet and 35% (w/vol) sucrose solution in 120 
mineral water as the only source of liquid intake. The diets were chosen with the aim of 121 
mimicking real nutritional conditions in humans who consume a moderate excess of fat 122 
or sugar (glucose + fructose). All the animals were fed ad libitum with free access to 123 
water or sucrose solution. 124 
Fecal samples were collected by abdominal massage at the start of the experiment 125 
(time 0) and after weeks 1, 3, 9, 12, 20 and 24. The energy content of the feces from 126 
week 20 was determined by differential scanning calorimetry using a TGA/SDTA851e 127 
thermobalance (Mettler Toledo; Columbus, OH, USA) with an integrated SDTA signal. 128 
After weeks 10 and 16, blood samples were collected from the saphenous vein after 129 
6overnight fasting. After week 23, the rats were placed in metabolic cages for urine 130 
collection. After week 24, they were fasted overnight and anaesthetized 131 
intraperitoneally with ketamine (Merial Laboratorios, Barcelona, Spain) and xylazine 132 
(Química Farmacéutica, Barcelona, Spain) at doses of 80 and 10 mg/kg body weight, 133 
respectively. Blood was collected by cardiac puncture and plasma was immediately 134 
obtained by centrifugation. Perigonadal fat, quadricep muscle and liver samples were 135 
collected, washed with 0.9% NaCl solution, weighed and immediately frozen in liquid 136 
N2. All the samples were stored at Ð80 ºC until analysis. 137 
Biometric measurements. Feed and drink intake as well as body weight were 138 
measured weekly. Feed and drink intake per day as a function of body weight were 139 
estimated by dividing the total intake per cage by the weight of the animals in that cage 140 
and the number of days and then they were averaged over the total number of cages in a 141 
group. Fat and fructose intake were calculated from the experimental measurements and 142 
the composition of the feed and drink: fat, 0.04 g/g standard feed (groups STD and HS) 143 
and 0.23 g/g HF feed (HF group); and fructose, 0.175 g/mL water (HS group) and 0.17 144 
g/g HF feed (HF group). Energy intake was calculated as estimates of metabolizable 145 
energy based on the Atwater factors, assigning 4 kcal/g protein, 9 kcal/g fat, and 4 146 
kcal/g available carbohydrate.147 
Systolic and diastolic blood pressure was measured at time 0 and after weeks 4, 9, 148 
15 and 22 by the tail-cuff method, using a non-invasive automatic blood pressure 149 
analyzer (Harvard Apparatus, Holliston, MA, USA). 150 
Measurement of uric acid. Total urine uric acid was determined by a 151 
spectrophotometric method using a uricase/peroxidase kit from BioSystems (Barcelona, 152 
Spain) by measuring the absorbance at 520 nm on a SpectraMax M5 spectrophotometer 153 
(Molecular Devices, Sunnyvale, CA, USA). Creatinine levels in urine were determined 154 
7by a colorimetric method using a commercial kit (C-cromatest Linear Chemicals, 155 
Montgat, Spain) by measuring absorbance at 510 nm.156 
Glycemic status. Fasting blood glucose and plasma insulin levels were measured 157 
after weeks 10 and 16 on fasted animals. Blood glucose concentration was measured by 158 
the enzyme electrode method, using an Ascensia ELITE XL blood glucose meter (Bayer 159 
Consumer Care AG, Basel, Switzerland); plasma insulin levels were measured using 160 
Milliplex xMAP multiplex technology on a Luminex xMAP instrument (Millipore, 161 
Austin, TX, USA). The standard curve was generated for the range 69-50,000 pg/mL, 162 
using a five-parameter logistic curve fit. Homeostasis model assessment for insulin 163 
resistance (HOMA-IR) was calculated according to the formula HOMA-IR=fasting 164 
blood glucose in mmol/L times fasting plasma insulin in U/mL divided by 405 (31). 165 
Insulin units (U) were calculated using the conversion 1U = 0.0347 mg insulin. Oral 166 
glucose tolerance tests (OGTT) were performed after weeks 13 and 21 on fasted 167 
animals. A solution of glucose (1 g/kg body weight) was administered by oral gavage 168 
before the tests and blood glucose concentration measured 15, 30, 45, 60, 90 and 120 169 
min after glucose intake.  170 
Histology of the liver. Fixed livers were dehydrated in alcohol and embedded in 171 
paraffin, then cut into 3 µm thick slices, using an HM 355S Rotary Microtome (Thermo 172 
Fisher Scientific, Waltham, MA, USA). Sections were stained with hematoxylin 173 
(hematoxylin solution modified acc to Gill III for microscopy; Merck KGaA, 174 
Darmstadt, Germany) mixed with eosin (Pharmacy Service of Puerta del Mar Hospital, 175 
Cádiz, Spain). The tissue sections were viewed under a NIKON Eclipse 80i light 176 
microscope (NIKON Corporation, Minato, Japan). Three variables were graded 177 
following the method described by Taltavull et al. (48): steatosis, 0 to 3; steatosis 178 
localization, 0 to 3; lobular inflammation with lymphoplasmacytic inflammatory 179 
8infiltration, 0 to 3; and the presence of microgranulomas.180 
Measurement of diacylglycerols. Frozen samples of liver, muscle and adipose tissue 181 
(AT) were weighed and sonicated (SFX150 Sonifier; Emerson Industrial Automation, 182 
St. Louis, MO, USA) until total homogenization. Diacylglycerol (DAG) extracts were 183 
prepared in the presence of BHT (butylated hydroxytoluene, 0.01%) and analyzed using 184 
a reported method (46) with some modifications. The mixtures were fortified with an 185 
internal standard (1,3-17:0 D5 DG, Avanti Polar Lipids Inc., Alabaster, AL, USA; 200 186 
pmol) and incubated overnight at 48 ºC. After solvent evaporation, the samples were 187 
suspended in methanol, centrifuged (9390 g, 3 min) and the supernatants loaded into an 188 
Acquity UPLC system connected to an LCT Premier orthogonal accelerated time-of-189 
flight mass spectrometer (Waters, Milford, MA, USA), operated in positive ESI mode. 190 
Full-scan spectra from 50 to 1,500 Da were acquired, and individual spectra were 191 
summed to produce data points of 0.2 s each. Mass accuracy and precision were 192 
maintained by using an independent reference spray (leucine enkephalin) via the 193 
LockSpray interference. A C8 Acquity UPLC-bridged ethylene hybrid 100 x 2.1 mm 194 
inner diameter, 1.7 m column (Waters) was used in the separation step. The samples (8 195 
µL) were eluted with a binary system consisting of 0.2% (v/v) formic acid, 2 mM 196 
ammonium formate in water [A] and in methanol [B] under linear gradient conditions: 197 
0.0 min, 80% B; 3 min, 90% B; 6 min, 90% B; 15 min, 99% B; 18 min, 99% B; 20 min, 198 
80% B; and 22 min, 80% B, at 30 ºC. The flow rate was 0.3 ml/min. Quantification was 199 
carried out using the extracted ion chromatogram of each compound, using 50 mDa 200 
windows.201 
Subpopulations of gut microbiota. The levels of total bacteria and Bacteroidetes, 202 
Firmicutes, Enterobacteriales, and Escherichia coli were estimated from fecal DNA by 203 
quantitative real-time polymerase chain reaction (qRT-PCR). DNA was extracted from 204 
9feces using QIAamp® DNA Stool Mini Kit from QIAGEN (Hilden, Germany) and 205 
quantified using a Nanodrop 8000 Spectrophotometer (ThermoScientific, Waltham, 206 
MA, USA). DNA samples were diluted to 20 ng/µL and qRT-PCR was carried out on a 207 
LightCycler® 480 II (Roche, Basel, Switzerland) in triplicate. The samples contained 208 
DNA (2 µL) and a master mix (18 µL) made of 2X SYBR (10 µL), the corresponding 209 
forward and reverse primer (1 L each), and water (6 µL). All reactions were paralleled 210 
by analysis of a non-template control (water) and a positive control. The primers and 211 
annealing temperatures are detailed in Table 1. Total bacteria were normalized as 16S 212 
rRNA gene copies per mg of wet feces (copies/mg). 213 
Measurement of short-chain fatty acids. Short-chain fatty acids (SCFAs) in feces 214 
were analyzed after week 12 by gas chromatography (GC) using a reported method (45) 215 
with some modifications. SCFAs were extracted from freeze-dried feces (~50 mg) with 216 
a mixture consisting of acetonitrile/water 3:7 (1 mL), and the internal standard 2-217 
ethylbutiric acid (0.1 mL, 100 mg/L) and 0.1 M oxalic acid (0.5 mL) both in the same 218 
solvent, for 10 min using a horizontal shaker. Finally, the suspension was centrifuged 219 
(12880 g, 5 min) in a 5810R centrifuge (Eppendorf, Hamburg, Germany) and the 220 
supernatant passed through a 0.45 m nylon filter. Aliquots (0.7 mL) were diluted to 1 221 
mL with acetonitrile/water 3:7 and the SCFAs were analyzed using a Trace2000 gas 222 
chromatograph (ThermoFinnigan, Waltham, MA, USA) coupled to a flame ionization 223 
detector equipped with an Innowax 30 m × 530 µm × 1 µm capillary column (Agilent, 224 
Sta. Clara, CA, USA). The method showed good selectivity for acetic acid, propionic 225 
acid, butyric acid, isobutyric acid valeric acid and isovaleric acid; sensitivity; linearity;226 
and accuracy (trueness and precision). To check the method trueness and precision, a 227 
recovery study at three concentrations was performed on three different days. Precision 228 
(RSD < 15%) and recovery (> 70%) were adequate; as was intra-day reproducible.229 
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Biomarkers and lipid mediators of inflammation. Plasma lipopolysaccharide (LPS) 230 
concentration was estimated by reaction with Limulus amoebocyte extract: LAL kit 231 
endpoint-QCL1000 (Cambrex BioScience, Walkersville, MD, USA). Plasma samples 232 
collected at the end of the study under sterile conditions were diluted 70-fold and heated 233 
for 20 cycles of 10 min at 68 ºC and 10 min at 4 ºC each. An internal control for LPS 234 
recovery was included.235 
Levels of plasma interleukin-6 (IL-6) were measured using Milliplex xMAP multiplex 236 
technology. Liver function was ascertained by measuring the activities of alanine 237 
transaminase (AST) and aspartate transaminase (ALT) in plasma by a spectrophometric 238 
method using kits from Spinreact (Sant Esteve de Bas, Spain) and it is expressed as the 239 
AST/ALT ratio. 240 
Lipid mediators from the metabolism of arachidonic acid (ARA), eicosapentaenoic 241 
acid (EPA) and docosahexaenoic acid (DHA) were determined in plasma by liquid 242 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) using a method 243 
modified from Dasilva et al. (6). Erythrocyte-free plasma samples (90 µL) were thawed, 244 
diluted in the presence of BHT and spiked with the internal standard 12HETE-d8 245 
(Cayman Chemicals, Ann Arbor, MI, USA). Then, the samples were centrifuged (800 g, 246 
10 min) and the lipids in the supernatants were purified by SPE. The LC-MS/MS 247 
analyzer consisted of an Agilent 1260 Series chromatograph (Agilent) coupled to a 248 
dual-pressure linear ion trap mass spectrometer LTQ Velos Pro (Thermo Fisher, 249 
Rockford, IL, USA) operated in negative ESI mode. A C18-Symmetry 150 × 2.1 mm 250 
inner diameter, 3.5 m column (Waters) with a C18 4 × 2 mm guard cartridge 251 
(Phenomenex, Torrance, CA, USA) were used in the separation step. Samples (10 µL) 252 
were eluted with a binary system consisting of [A] 0.02% aqueous formic acid and [B] 253 
0.02% formic acid in methanol under gradient conditions of: time 0, 60% B; 2 min, 254 
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60% B; 12 min, 80% B; 13 min, 80% B; 23 min, 100% B; 25 min, 100% B; and 30 min, 255 
60% B, at a flow rate of 0.2 mL/min.  256 
Measurement of isoprostanes. F2-isoprostanes (F2-IsoPs) were determined in urine 257 
samples by LC/ESIMS/MS following a previously reported procedure (35) with 258 
modifications. Urine samples (500 µL) were acidified, -glucuronidase (90 U/mL) 259 
(Sigma, Saint Louis, MI, USA) was added and the mixtures were incubated for 2 h at 37 260 
ºC. After addition of the internal standard [2H4]15-F2t-IsoP (Cayman, Ann Arbor, MI, 261 
USA) (100 µL, 10 µg/L), F2-IsoPs were purified by SPE. F2-IsoPs were analyzed using 262 
an Agilent 1260 chromatograph fitted with a Mediterranea Sea 18 column (10 cm x 2.1 263 
mm i.d., 2.2 µm particle size) (Teknokroma, Barcelona, Spain) coupled to a 4000 264 
QTRAP mass spectrometer (Applied Biosystems, Foster City, CA, USA). The 265 
instrument was operated in the negative-ion mode with a Turbo V source to obtain 266 
MS/MS data. Separation was achieved with a binary system consisting of [A] 0.1% 267 
aqueous formic acid and [B] 0.1% formic acid in acetonitrile, at 40º C, with an 268 
increasing linear gradient (v/v) of [B]: time 0, 10% B; 7 min, 50% B; 7.1 min, 100% B; 269 
8 min, 100% B; 8.1 min, 10% B; and 10 min, 10% B, at a flow rate of 700 µL/min. F2-270 
IsoPs were detected by MS/MS multiple reaction monitoring (MRM). Calibration 271 
curves were prepared using seven matrix-matched standards covering the working 272 
concentration range. The LOQ was 0.4 µg/L for 15-F2t-IsoP and 2 µg/L for 5-F2t-IsoP. 273 
The results were expressed as ng/mg creatinine, to correct for urine dilution. 274 
Statistical analysis. All data manipulation and statistical analysis was performed 275 
using Graph Pad Prism 5 (Graph Pad Software, Inc., San Diego, CA, USA). The results 276 
are expressed as mean values with their standard errors (SEM). Normal distribution and 277 
heterogeneity of data were evaluated and statistical significance was determined by two-278 
way ANOVA for repeated measurements or one-way ANOVA, and Tukeys multiple 279 
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comparisons test was used for mean comparison. Differences were considered 280 
significant when P < 0.05. 281 
282 
RESULTS 283 
Feed and drink intakes, and energy balance. Feed intake was lower in animals fed 284 
the HF diet than in those in the STD group and even lower in animals given the HS diet 285 
(Table 2). Drink intake was higher in animals in the HS group than in those from the 286 
other two groups. Energy intake was higher in both the HF and HS groups than in the 287 
STD group. Residual energy in feces was similar in the STD and HF groups, and lower 288 
in the HS group (P < 0.05 vs HF). The HF animals consumed significantly (P < 0.001) 289 
more fat than the other two groups throughout the experiment (Figure 1A); while HS 290 
rats consumed significantly (P < 0.001) more fructose (Figure 1B) per 100 g of body 291 
weight than rats in the other groups. As the only source of carbohydrate in the HF diet 292 
was sucrose (equimolar fructose and glucose), the rats in this group consumed as much 293 
glucose as fructose. 294 
Weight gain and lipid accumulation. Body weight was similar in all the groups at 295 
the beginning (235.9 g, SEM 3.6) and no differences were observed between the STD 296 
and HS groups during the whole experiment (Figure 1C). After 6 weeks, the HF group 297 
had significantly (P < 0.001) increased body weight (352.0 g, SEM 10.8) compared to 298 
the STD (305.9 g, SEM 7.3) and HS (292.4 g, 9.1) groups; and the differences in weight 299 
gain increased until the end of the study (STD: 416.4 g, SEM 12.9; HF: 544.3 g, SEM 300 
15.5, after week 24). Perigonadal AT weight was significantly (P < 0.001) higher in the 301 
HF group than in the other two groups (Figure 1E).302 
Blood pressure and urine uric acid. Systolic and diastolic blood pressures (Figure 303 
1D) were similar in the STD and HF groups throughout the experiment. After 23 weeks 304 
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of intervention, systolic blood pressure was significantly higher (P < 0.001) in animals 305 
given the HS diet than in those given the STD or HF diet. Diastolic blood pressure was 306 
higher (P < 0.05 vs STD) in HS-fed animals from week 9 to week 23. Animals fed HS 307 
presented a significantly (P < 0.001) higher concentration of uric acid in urine at week 308 
23 than those of the STD and HF groups (Figure 1F).309 
Glycemic status. Fasting blood glucose and plasma insulin concentration were measured 310 
after weeks 10 and 16 of the intervention (Table 3). HOMA-IR is used as an indicator of 311 
IR. At both times, both fasting glucose and insulin as well as HOMA-IR were 312 
significantly higher in the HF group than in the STD group. After 16 weeks of 313 
intervention, the plasma insulin concentration and HOMA-IR in the HS group were not 314 
different from the values in either the STD or the HF group (Table 3). The OGTT was 315 
performed twice during the study, after weeks 13 and 21 (Figure 2). The increase of the 316 
area under the curve (AUC) is as an indicator of IGT. After 13 weeks, the levels of 317 
postprandial glucose in the HF group were higher than those in the other groups (STD 318 
and HS), 30 and 60 min after administration (Figure 2). The AUC corresponding to the 319 
HF group was significantly higher (P < 0.001) than that in the STD group. By the end of 320 
the study (week 21), the plasma glucose levels in groups HF and HS were similar and 321 
significantly higher than those of the STD group at all the time points (Figure 2).  322 
Liver histology, total liver triacylglycerols and biochemical measurement of liver 323 
function. An excess of dietary fat triggered lobular inflammation and microgranulomas, 324 
while an excess of fructose did not (Figure 3A). The livers of animals fed the HF diet 325 
showed lobular inflammation with lymphoplasmacytic inflammatory infiltration around 326 
the blood vessels (e.g. Figure 3C). Conversely, an excess of fructose induced significant 327 
and highly localized steatosis (Figure 3A, D) while an excess of dietary fat did not 328 
(Figure 3A, C). The levels of total triacylglycerols (mol/g liver) were STD: 46.8, SEM 329 
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20.1; HF: 80.4, SEM 19.7; HS: 168.1, SEM 92.6, with no significant differences 330 
between the groups. No liver functional damage resulted from any of the diets as 331 
revealed by the similar AST/ALT ratio in the three groups (STD: 6.7, SEM 0.6; HF: 6.3, 332 
SEM 0.8; HS: 5.7, SEM 1.2)333 
Diacylglycerols in tissues. The levels of saturated DAGs 38:0 and 40:0, and 334 
unsaturated DAGs 34:2, 34:3, 34:4, 36:5, and 40:5, were lower in liver in the HF group 335 
than in the STD and/or HS groups (Table 4). The levels of unsaturated DAGs 32:1, 336 
32:2, 34:1, and 36:2 were higher in animals that consumed an excess of fructose than in 337 
animals in the other two groups; whereas the levels of DAG 42:12 were lower. The 338 
levels of DAGs 36:4, 36:6, 38:1, and 38:6, were lower in both HS and HF groups than 339 
in the STD group.340 
In muscle (Table 5), the levels of DAGs 34:3, 38:3, 38:4, 38:5, and 40:5 were lower 341 
in the HF group than in the STD group; whereas the levels of DAG 36:1 were higher. 342 
The levels of unsaturated DAG 32:1 were higher in the HS group than in the other two 343 
groups (STD and HF). The levels of DAG 34:1 were higher and those of 36:4 were 344 
lower in both HS and HF groups than in the STD group. In perigonadal AT (Table 6), 345 
only the levels of DAG 42:1 were higher in the HF group than in the other two groups 346 
(STD and HS). The levels of unsaturated DAGs 32:3, 36:1, 36:2, 38:2, and 40:3 were 347 
lower in animals that consumed an excess of fructose than in animals in the STD or HF 348 
groups. The levels of DAGs 34:1, 34:2, 34:3, 34:4, 36:3, 36:4, 36:5, 36:6, 38:3, 38:4, 349 
38:5, 38:6, and 40:5 were lower in both HS and HF groups than in the STD group. 350 
Subpopulations of gut microbiota and microbial products. The 351 
Bacteroidetes:Firmicutes ratio (Figure 4A) was reduced in HF animals and increased in 352 
HS animals compared to STD animals. The proportion of Enterobacteriales and E. coli 353 
in animals given the HF diet were already significantly increased after weeks 1 and 3, 354 
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and tended to decrease gradually afterwards (Figure 4B, C). An excess of fructose only 355 
increased the populations of Enterobacteriales and E. coli at the end of the study (Figure 356 
4B, C).357 
The levels of acetic, propionic and isobutyric acids, and total SCFAs were lower in 358 
the feces of HF animals than in those fed the STD or HS diet (Table 7).  359 
The HF animals showed a non-significant tendency (P = 0.1 vs STD group) towards 360 
increased plasma concentration of LPS at the end of the study (Figure 5A). The HS 361 
animals did not show any increase in plasma LPS. 362 
Markers and lipid mediators of inflammation. The animals fed the HF diet showed 363 
increased plasma concentrations of IL-6 and prostaglandin E2 (PGE2, EPA metabolite) 364 
compared to the STD group at the end of the study (Figure 5B, C). The concentrations 365 
of ARA, EPA and DHA were higher in the HS group than in the STD and HF groups 366 
(Figure 5D, E, F). No differences were detected in the concentration of LTB4367 
(leukotriene B4) or 12HEPE (12-hydroxyeicosapentaenoic acid), ARA and EPA 368 
metabolites, respectively (Figure 5G, H). The concentration of the DHA metabolite 369 
17HDoHE (17-hydroxy docosahexaenoic acid) was lower in animals fed the HS diet 370 
than in those fed the HF diet (Figure 5I).371 
Isoprostanes as markers of oxidative stress. The animals fed HS showed increased 372 
concentrations of 5-F2t-IsoP and 15-F2t-IsoP (P < 0.05) compared to the STD and HF 373 
groups after 23 weeks of intervention (Figure 6A, B).  374 
DISCUSSION375 
The present study explores some molecular factors behind the differential action of 376 
an excess of dietary fat or of fructose on normal rats and examines the role that gut 377 
microbiota may play in these processes. A prediabetic state was induced to WKY rats by 378 
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HF or HS1 diets over a period of 24 weeks. Despite all the information available on the 379 
induction of IR and IGT by fat and fructose in rat models, the molecular mechanisms 380 
behind this action are still largely unknown. In our models, fat induced a prediabetic 381 
state faster than fructose, as evidenced by the results of fasting blood glucose, plasma 382 
insulin concentration, HOMA-IR (Table 3) and the OGTT (Figure 2). Only the animals 383 
in the HF group presented both IR (HOMA-IR) and IGT (OGGT). The rats that 384 
consumed and excess of sugar showed a tendency towards elevated plasma insulin and 385 
significant IGT only at the end of the study (Table 3 and Figure 2). The differences in 386 
timing between the metabolic response to fat and fructose prompted us to explore the 387 
changes induced in some molecular factors known to be mechanistically related to the 388 
development of IR and IGT. As low-grade inflammation may trigger IR, we measured 389 
inflammation markers in the two models. Unlike the rats in the HS group, the livers of 390 
HF-fed animals clearly presented inflammatory infiltrations within the portal space 391 
(Figure 3). This is a sign of systemic inflammation that was confirmed by the plasma 392 
levels of IL-6 and PGE2 (Figure 5B, C). IL-6 and other inflammatory markers are 393 
elevated in obesity-induced low-grade inflammation-related IR (11, 25); ARA-derived 394 
cyclooxygenase (COX)-mediated pro-inflammatory factor PGE2 is the predominant 395 
prostaglandin in white AT, where it regulates adipose functions (26). PGE2 also inhibits 396 
pancreatic beta cell function and insulin secretion (43) which is an effect characteristic 397 
of intermediate stages of diabetes, beyond the initial increase in insulin secretion (IR, 398 
compensation stage) (50). Conversely, potentially anti-inflammatory EPA and DHA 399 
were elevated in animals given an excess of fructose (Figure 5E, F). EPA and DHA are 400 
considered to protect against inflammation mainly because they compete with ARA for 401 
1 In our HS model, IR and probably hypertension are more likely to be triggered by the excess of fructose 
than by glucose, as glucose can be metabolized and/or stored as glycogen in different organs (e.g. brain, 
liver and muscle) and it is carefully controlled by insulin everywhere, while fructose is almost entirely 
processed, mainly in the liver, and escapes metabolic control by insulin (18). 
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the same metabolizing enzymes, and also because they generate protectins and resolvins 402 
as metabolites (7, 30). So, the HF animals presented systemic inflammation; while the 403 
HS diet not only did not trigger early systemic inflammation, but also may have favored 404 
anti-inflammatory pathways.  405 
The observation of a non-significant trend (P = 0.1) toward elevated plasma LPS 406 
concentrations (Figure 5A) suggested that microbial-derived endotoxemia might 407 
contribute to the low-grade inflammation in HF-fed animals. LPS is a component of the 408 
wall of Gram-negative bacteria present in Bacteroidetes and Enterobacteriales but not in 409 
Firmicutes. As the population of Bacteroidetes clearly decreased in HF animals with 410 
respect to STD rats (Figure 4A), the increase in LPS and pro-inflammatory mediators 411 
detected in the plasma of HF animals (Figure 5A, B, C) might originate from 412 
Enterobacteriales (Figure 4B), particularly its major member E. coli (Figure 4C). This 413 
agrees with observations by other authors (8, 15). Additional research should confirm or 414 
refute this suggestion. In addition to LPS, other mediators proposed as the link between 415 
gut bacteria and metabolic alterations are bile acids, angiopoietin-like protein 4 and 416 
SCFAs: products of microbial fermentation of dietary fiber (23). SCFAs acetate and 417 
butyrate generated by Firmicutes may contribute to body fat gain through de novo418 
lipogenesis (2). Together with propionate, these SCFAs exhibit a protective effect 419 
against inflammation and IR (2). In apparent contradiction, the animals that presented 420 
the lowest Bacteroidetes:Firmicutes ratio and gained most weight (HF group) generated 421 
the lowest amounts of total SCFAs (Table 7). This may be due to the composition of the 422 
diet. Whereas the standard diet (fed to the STD and HS groups) contains wheat 423 
middlings, ground wheat and ground corn, the only source of fiber in the HF diet is 424 
cellulose (50 g/kg). The lower diversity in the source of fiber may be the cause of the 425 
reduced production of protective SCFAs.   426 
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As DAGs may induce IR independently of inflammation, we measured their levels 427 
in liver, muscle and AT. We did not detect any significant increase in the DAG profile in 428 
the livers of rats fed HF (Table 4), in agreement with the absence of steatosis (Figure 429 
3C). The only DAGs with elevated levels in the HF group were the monounsaturated 430 
34:1 (muscle), 36:1 (muscle) and 42:1 (AT). As lipid-induced IR occurs earlier in liver 431 
than in muscle (28), we concluded that direct impairment of insulin signaling by lipid 432 
metabolites would not explain the observed early fat-induced systemic IGT. In contrast, 433 
the animals given an excess of fructose presented steatosis around the blood vessels 434 
(Figure 3D) and clearly elevated DAGs in the liver (Table 4) without gaining more 435 
weight or accumulating more perigonadal AT than those given the STD diet (Figure 1C, 436 
E). The levels of total triglycerides were also elevated in the HS group although the 437 
differences were not statistically significant probably due to the fact that the steatosis 438 
was highly localized. These observations are consistent with hepatic de novo439 
lipogenesis from fructose (20). It is becoming evident that different DAGs have a very 440 
different impact on cellular signaling (13). While there is no information so far as to 441 
what particular DAG species might impair insulin signaling, it has been reported that 442 
cellular signaling proteins and receptors such as the human transfer receptor potential 443 
C3 (TRPC3) are differentially activated by different DAGs and that DAG 36:2 (1-444 
stearoyl-2-linoleoyl-sn-glycerol) is one of the active species (21, 38). The amounts of 445 
DAGs 36:2 and 34:1 (putatively 1-palmitoyl-2-oleoyl-sn-glycerol ) were dramatically 446 
increased (3- to 4-fold) in the livers of HS-fed rats (Table 4), which suggests that DAG 447 
36:2 may play a role in late fructose-induced tendency to IR. DAG 34:1, which does not 448 
activate the TRCP3 calcium channel (38), may or may not play a role in our model. In 449 
muscle, DAG content is much lower than in liver and only the levels of DAG 32:1 were 450 
slightly elevated in the muscular tissue of animals given the HS diet; and those of DAG 451 
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34:1 in both the HF and HS groups (Table 5). As expected, perigonadal AT presented 452 
the highest levels of DAGs in all groups (Table 6). None of the significant differences 453 
detected corresponded to any increase in DAG levels in the HF or HS group. The 454 
overall examination of DAG variations in liver, muscle and AT showed that the only 455 
likely contribution of these lipid metabolites to IR or IGT takes place in the liver of HS-456 
fed rats and that DAGs may not play a significant role in the development of IR or IGT 457 
in rats fed an HF diet. 458 
The levels of urine F2-IsoPs, which are products of free radical-mediated in vivo459 
oxidation of ARA (33) different from COX-derived oxidized prostaglandins such as 460 
PGE2, were only elevated in animals given an excess of fructose at the end of the study 461 
(Figure 6), consistently with increased levels of ARA (Figure 5D). This implies that an 462 
excess of dietary fat did not trigger significant low-grade inflammation-mediated 463 
systemic oxidative stress (OS), which may be attributed to the action of the excess of 464 
fructose. In agreement with this observation, increased generation of superoxide radical 465 
has been detected in the kidneys of high fructose-fed rats (40). The results also indicate 466 
that IR per se does not trigger systemic OS, as the animals given an excess of fat 467 
developed IR and IGT for the duration of the entire experiment (Table 3, Figure 2) 468 
while showing IsoP levels similar to those in the STD group (Figure 6). In contrast with 469 
our results, other authors have linked fructose-induced OS to inflammation and 470 
hyperinsulinemia (4, 40). Those experiments were performed on SpragueDawley rats 471 
using shorter intervention times (3-12 weeks). In our experiment (WKY rats), if the 472 
inflammatory response was associated with OS in an early compensatory stage 473 
(stimulation of insulin secretion) (50), it was no longer evident after 24 weeks of 474 
intervention. 475 
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In the present study, only the HS diet induced hypertension which was statistically 476 
significant after 9 weeks (diastolic pressure) and 22 weeks (systolic pressure) (Figure 477 
1D). As rats in this group consumed significantly more sugar and water than those given 478 
the STD or HF diets, the hypertensive effect may be explained, at least in part, by water 479 
movement from tissues into the intravascular space caused by elevated levels of blood 480 
glucose (41) together with hyperhydration. The high amounts of fructose available in 481 
the liver of rats given the HS diet may also have caused elevated blood pressure via the 482 
formation of uric acid (32) which is biosynthesized through the degradation of AMP to 483 
inosine monophosphate following a fall in intracellular phosphate that originates in the 484 
rapid and uncontrolled phosphorylation of fructose (24). This explanation is supported 485 
by our observation that the HS group shows significantly higher levels of urine uric acid 486 
than the STD and HF groups (Figure 1F). Late mild IR (Table 3) and IGT (Figure 2) 487 
may also contribute to the elevated blood pressure in the HS group, as described in 488 
previous studies (49). It should be noted that only hepatic IR (HS group) would in any 489 
case bring about hypertension as the animals showing early IR (HF group, Table 3) were 490 
normotensive (Figure 1D). The observation that the populations of Enterobacteriales 491 
and particularly E. coli only increased in the feces of animals in the HS group (Figure 492 
4B, C) when IGT became significantly high (week 21, Figure 2) suggests a relationship 493 
between gut bacteria and late fructose-related metabolic alterations. In this case though, 494 
the diet is less likely to induce late changes in the intestine, therefore the increase in 495 
bacterial populations may be a consequence of the systemic action of the diet rather than 496 
a cause of it. It has been reported that intestinal uric acid in end-stage renal disease 497 
(ESRD) patients increases the populations of bacteria that are able to catabolize uric 498 
acid into urea and eventually ammonia (51). As part of the uric acid is excreted through 499 
the gut in both humans and rats (19, 47), we hypothesize that uric acid generated by 500 
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high fructose-fed rats (Figure 1F) may contribute to the increase in the populations of 501 
gut Enterobacteriales (Figure 4B), which are microorganisms known to use urease to 502 
metabolize urea (5, 34). To test this hypothesis it may be worth monitoring changes in 503 
the gut populations of microorganisms known to metabolize uric acid into urea. The late 504 
increase in Enterobacteriales might trigger further inflammation. 505 
506 
CONCLUDING REMARKS 507 
This paper examines two rat models of prediabetes with clearly differentiated 508 
mechanisms than can be used to test the effects of drugs and food ingredients. As the 509 
effects induced are mild, the models are particular suited for testing functional food 510 
ingredients. A high-fat diet induced obesity and fast IR and IGT via low-grade 511 
inflammation in WKY rats. In contrast, a high-sucrose (fructose + glucose) diet induced 512 
IGT later than the HF diet, by processes triggered by de novo liposynthesis from 513 
fructose, probably mediated by active DAGs in the liver. Neither low-grade 514 
inflammation (HF group) nor localized steatosis (HS group) severely affected liver 515 
function as assessed by measuring the AST/ALT ratio. Hypertension in HS-fed rats may 516 
be due to causes other than systemic IR that include an excess of water/glucose intake 517 
and the generation of uric acid from fructose. The development of IR coincides with 518 
increased populations of E. coli in the intestinal tract that may contribute to low-grade 519 
inflammation in HF-fed animals or may be a consequence of the metabolic alterations 520 
of an excess of fructose in HS-fed animals. The results show that fat and sugar trigger 521 
metabolic alterations by largely independent mechanisms and underscore the potentially 522 
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FIGURE CAPTIONS 678 
679 
680 
Figure 1. Fat intake (A), fructose intake (B), body weight (C), blood pressure (D), 681 
adipose tissue weight (E) and uric acid in urine (F) of rats (n = 9 per group) fed the 682 
standard (STD, ), high-fat (HF, ) or high-sucrose (HS, ) diet for 24 weeks.  683 
Data are presented as means with their standard errors. Comparisons were conducted 684 
using two-way ANOVA (A, B, C, D) or one-way ANOVA (E, F) and Tukeys multiple 685 
comparisons test. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group;  P < 686 
0.001 vs HF group. 687 
688 
689 
Figure 2. Glycemic response in rats (n = 9 per group) fed the standard (STD), high-fat 690 
(HF) or high-sucrose (HS) diet. Curves of OGTT after ingestion of a single dose of 691 
glucose (1 g/kg body weight) after weeks 13 and 21 of intervention, and the 692 
corresponding areas under the curve (AUC).  693 
Values are presented as means with their standard errors. Comparisons were conducted 694 
using two-way ANOVA (OGTT curves) or one-way ANOVA (AUCs) and Tukeys 695 
multiple comparisons test. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group;  P 696 
< 0.05 and  P < 0.01 vs HF group. 697 
698 
699 
Figure 3. Liver histology. Estimation of variables (A) and cuts stained with 700 
hematoxilin-eosin: rats fed the STD diet present normal liver (B, 20x), rats fed the HF 701 
diet present inflammatory infiltration within the portal triad without steatosis (C, 20x), 702 
30
and rats fed the HS diet present steatosis without inflammatory infiltration (D, 20x).  703 
Scores are presented as means with their standard errors. Comparisons were conducted 704 
using one-way ANOVA and Tukeys test. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs705 
STD group;  P < 0.05,  P < 0.01 and  P < 0.001 vs HF group. 706 
707 
708 
Figure 4. Excreted intestinal bacteria measured by qRT-PCR and expressed as 709 
percentages of total bacteria in fecal samples from rats (n = 9 per group) fed a standard 710 
diet (STD), high-fat diet (HF) or high-sucrose diet (HS) for 24 weeks of nutritional 711 
intervention. A,  Bacteroidetes/Firmicutes ratio; B, Enterobacteriales; and C, E. coli.  712 
Results are presented as means with their standard errors. Comparisons were conducted 713 
using one-way ANOVA and Tukeys multiple comparisons test. * P < 0.05, ** P < 0.01 714 




Figure 5. Plasma biomarkers of inflammation from rats (n = 9 per group) fed a standard 719 
diet (STD), high-fat diet (HF) or high-sucrose diet (HS) for 24 weeks of nutritional 720 
intervention. A, Lipopolysaccharide; B, IL-6 (determined after 10 weeks of 721 
intervention); C, PGE2; D, arachidonic acid (ARA); E, eicosapentaenoic acid (EPA); F 722 
docosahexaenoic acid (DHA); F, LTB4; H, 12HEPE; and I 17HDoHE.  723 
Results are presented as means with their standard errors. Comparisons were conducted 724 
using one-way ANOVA and Tukeys multiple comparisons test. * P < 0.05 and ** P < 725 




Figure 6. Isoprostanes in urine from rats (n = 9 per group) fed a standard diet (STD), 729 
high-fat diet (HF), and high-sucrose diet (HS) for 24 weeks of nutritional intervention.  730 
A, 5F2t; B, 15F2t.  731 
Results are presented as means with their standard errors. Comparisons were conducted 732 
using one-way ANOVA and Tukeys multiple comparisons test. * P < 0.05 vs STD 733 




Table 1. qRT-PCR primers and conditions737 
738 





Total Bacteria # 65 F: ACT CCT ACG GGA GGC AGC AGT (18) 
R: ATT ACC GCG GCT GCT GGC  
Bacteroidetes Bacteroides 
fragilis 
62 F: ACG CTA GCT ACA GGC TTA A (22) 




F: AGA GTT TGA TCC TGG CTC (17) 
R: ATT ACC GCG GCT GCT GG (37) 
Enterobacteriales E. coli M15 60 F: ATG GCT GTC GTC AGC TCG T (18) 
R: CCT ACT TCT TTT GCA ACC CAC T  
E. coli E. coli M15 61 F:  GTT AAT ACC TTT GCT CAT TGA (29) 
R: ACC AGG GTA TCT AAT CCT GTT  
739 
# Positive control of Total Bacteria was the strain the result was rated with. 740 
741 
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Table 2. Feed, drink and energy intakes of rats fed different diets for 24 weeks, and 742 
residual excreted energy in feces after 20 weeks of intervention.743 
STD HF HS 
Mean SEM Mean SEM Mean SEM
Feed intake  
(g/day/100 g body weight) 5.4 0.3 4.1* 0.3 2.7*
 0.2 
Drink intake  
(mL/day/100 g body weight) 7.2 0.3 5.5 0.3 10.7*
 0.3 
Total energy intake  
(kcal/day/100 g body weight) 15.5 0.8 19.5* 1.2 22.8* 0.8 
Energy in fecesa 307 19 362 72 292 17 
744 
Data are presented as means with their standard errors of the mean, n = 9 per group. 745 
Comparisons were performed using one-way ANOVA and Tukeys multiple 746 
comparisons test.747 
*P < 0.05 vs STD group; P < 0.05 vs HF group. 748 




Table 3. Fasting plasma glucose and insulin concentration and calculated HOMA-IR.752 
STD HF HS 
Mean SEM Mean SEM Mean SEM 
week 10 
Fasting glucose (mg/dL) 65.4 1.4 75.7*** 2.0 64.8 2.7
Insulin (pg/mL) 417.9 71.4 1737*** 137.6 584.5 105.8
HOMA-IR 1.9 0.3 9.3*** 0.7 2.7 0.5
week 16 
Fasting glucose (mg/dL) 66.0 1.1 70.8* 1.4 59.3  3.0
Insulin (pg/mL) 661.2 53.9 1654.8* 331,5 1090.1 203.6
HOMA-IR 3.1 0.2 8.4* 1.8 4.7 1.1
753 
Data are presented as means with their standard errors of the mean, n = 9 per group. 754 
Comparisons were conducted using one-way ANOVA and Tukeys multiple 755 
comparisons test. * P < 0.05 and *** P < 0.001 vs STD group;  P < 0.05,  P < 0.01, 756 
 P < 0.001 vs HF group. 757 
758 
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Table 4. Liver diacylglycerols (DAGs, nmol/g tissue#) by LC-MS . 759 
STD HF HS 
Mean SEM Mean SEM Mean SEM 
32:0 2332 504 2256 447 5224 2063 
34:0 7661 1676 8044 1469 17320 8406 
36:0 5598 1213 6116 1124 12040 5659 
38:0 296.3 53.3 139.1* 24.9 208.9 32.7 
40:0 32.5 5.0 14.3** 14.3 22.0 3.3 
32:1 64.3 6.8 69.2 12.7 242.6* 72.1 
32:2 15.1 1.5 14.8 2.4 43.6* 12.5 
34:1 405.7 43.0 540.4 100.1 1499.0* 427.2 
34:2 328.8 39.1 139.6 26.6 414.6 111.1 
34:3 88.0 10.7 27.0* 6.0 101.7 26.7 
34:4 17.4 2.3 2.1* 1.4 18.1 6.5 
36:1 85.6 10.1 111.4 19.3 131.0 31.9 
36:2 321.4 35.0 576.4 117.5 1296.0* 380.6 
36:3 711.1 86.3 398.9 78.5 681.0 182.1 
36:4 381.7 48.8 102.1*** 18.7 203.0** 34.4 
36:5 50.5 6.3 8.3*** 2.6 29.6 8.5 
36:6 12.2 2.6 0.0*** 0.0 1.7** 1.7 
38:1 6.3 1.6 0.0*** 0.0 1.6* 1.1 
38:2 12.2 1.5 9.7 2.4 17.8 4.7 
38:3 18.5 5.1 17.6 4.5 21.0 5.2 
38:4 436.5 54.8 325.4 44.2 367.5 41.2 
38:5 220.1 25.2 131.8 23.0 170.2 35.3 
38:6 227.7 27.3 57.8*** 10.3 66.7*** 10.5 
40:5 171.8 27.1 90.6* 17.9 112.9 16.7 
42:5 141.9 22.2 80.6 17.4 80.4 10.2 
42:12 12.3 1.8 10.1 1.6 3.5** 1.3 
Data are presented as means with their standard errors of the mean,  760 
n = 9 per group. Comparisons were conducted using one-way ANOVA  761 
and Tukeys multiple comparisons test. 762 
* P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group;  P < 0.05 vs HF group. 763 
#Amounts expressed as DAG 16:0, 16:0 equivalents. 764 
765 
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Table 5. Muscle diacylglycerols (DAGs, nmol/g tissue#) by LC-MS766 
STD HF HS 
Mean SEM Mean SEM Mean SEM 
32:0 30.8 5.5 29.3 4.1 37.2 5.0 
34:0 47.1 14.6 41.2 10.7 47.4 15.5 
36:0 10.7 10.4 24.2 8.6 26.3 12.0 
38:0  3.8 1.5 2.5 0.9 4.1 1.8 
40:0 1.1 0.4 1.2 0.3 1.4 0.3 
42:0 0.4 0.2 0.5 0.2 0.7 0.2 
32:1 5.9 0.8 9.0 1.5 10.7* 0.8 
32:2 1.3 0.3 1.6 0.4 1.9 0.3 
34:1 29.3 4.2 52.2* 8.5 54.4* 3.0 
34:2 19.2 3.7 12.3 2.3 16.4 1.6 
34:3 4.6 0.9 2.4* 0.4 3.4 0.4 
36:1 4.0 0.7 8.5* 1.8 4.9 0.5 
36:2 15.5 2.9 33.8 8.3 30.9 3.2 
36:3 18.9 4.4 13.2 3.2 12.4 2.1 
36:4 11.5 2.1 4.6** 0.5 4.9** 0.5 
36:5 0.0 0.0 0.0 0.0 0.2* 0.1 
38:1 0.2 0.1 0.3 0.1 0.2 0.1 
38:2 0.7 0.3 0.6 0.1 0.8 0.2 
38:3 1.7 0.5 0.6* 0.1 0.8 0.2 
38:4 10.7 1.7 5.2** 0.5 7.3 1.0 
38:5 4.2 0.6 2.7* 0.3 3.2 0.3 
38:6 3.5 0.5 2.4 0.5 2.4 0.5 
40:5 1.3 0.4 0.1** 0.1 0.6 0.2 
42:1 0.1 0.1 0.2 0.1 0.5 0.1 
767 
Data are presented as means with their standard errors of the mean,  768 
n = 9 per group. Comparisons were conducted using one-way ANOVA  769 
and Tukeys tests. 770 
* P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group;  P < 0.01 vs HF  771 




Table 6. Adipose tissue diacylglycerols (DAGs, nmol/g tissue#) by LC-MS. 775 
776 
STD HF HS 
Mean SEM Mean SEM Mean SEM 
32:0  217.3 30.4 143.4 41.6 137.1 28.6 
34:0 50.1 6.2 63.2 21.7 21.1 4.2 
38:0  1.0 0.2 0.7 0.3 0.4 0.1 
40:0 0.4 0.1 0.3 0.1 0.2 0.1 
42:0 0.0 0.0 0.9 0.4 0.0 0.0 
32:1 258.3 54.6 281.9 89.9 210.0 48.4 
32:2 207.8 44.5 122.3 50.9 70.8 18.4 
32:3 26.8 6.9 10.7 5.0 4.2* 1.1 
34:1 880.9 106.0 471.6* 112.7 457.8* 81.0 
34:2 1338.0 164.7 400.6*** 127.2 436.9*** 85.7 
34:3 1337.0 153.3 449.2*** 125.3 404.2*** 83.3 
34:4 41.7 10.3 6.2*** 3.1 4.3*** 1.1 
36:1 93.8 11.5 213.3 74.7 39.9 8.6 
36:2 874.1 103.3 560.4 139.0 465.2* 83.4 
36:3 1337.0 153.2 449.2*** 125.3 404.2*** 83.3 
36:4 41.8 3.1 8.5*** 2.0 7.3*** 1.0 
36:5 120.1 20.0 9.2*** 4.3 4.8*** 1.6 
36:6 2.7 0.6 0.1*** 0.1 0.0*** 0.0 
38:1 4.5 1.2 2.5 2.1 0.5 0.4 
38:2 38.4 5.7 18.2 8.9 11.1* 3.0 
38:3 77.7 11.1 13.2*** 6.5 9.3*** 2.5 
38:4 55.7 7.3 6.9*** 2.5 3.2*** 0.5 
38:5 63.1 9.8 11.9*** 4.3 8.5*** 1.8 
38:6 2.5 0.3 0.4*** 0.1 0.3*** 0.0 
40:3 0.3 0.1 0.2 0.1 0.0** 0.0 
40:5 2.6 0.4 0.1*** 0.1 0.0*** 0.0 
42:1 0.2 0.1 1.0* 0.3 0.2 0.0 
777 
Data are presented as means with their standard errors of the mean, n = 9 per group. 778 
Comparisons were conducted using one-way ANOVA and Tukeys tests. 779 
* P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group;  P < 0.05 vs HF  780 





Table 7. Short-chain fatty acids (SCFAs, mmol/kg) in feces fed after 12 weeks785 
STD HF HS 
Mean SEM Mean SEM Mean SEM 
Acetic Acid  310.9 61.1 149.5* 17.6 265.5 45.6 
Propionic Acid 27.4 6.2 3.1** 0.6 28.0 5.7 
Isobutyric Acid 1.3 0.2 0.2*** 0.0 1.1 0.1 
Butyric Acid 17.6 3.3 6.2 1.6 23.1 5.8 
Isovaleric Acid 1.0 0.3 0.4 0.1 1.0 0.2 
Valeric Acid 0.7 0.1 0.4 0.1 1.1 0.2 
TOTAL SCFAs 356.9 66.1 159.4* 19.1 287.2 55.3 
786 
Data are presented as means with their standard errors of the mean, n = 9 per group. 787 
Comparisons were conducted using one-way ANOVA and Tukeys multiple 788 
comparisons test. 789 
* P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group;  P < 0.05,  P < 0.01 and  790 
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